$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
Precautions for patients with lung cancer using Xacori (crizotinib)
2025-10-19 11:44:20
Check Details
Efficacy and safety of crizotinib
2025-10-19 11:44:20
Check Details
Medical insurance reimbursement conditions for Xalkori (crizotinib) in 2021
2025-10-19 11:44:20
Check Details
Xalkori has very good results in the treatment of ALK-positive non-small cell lung cancer
2025-10-19 11:44:20
Check Details
Application of Xalkori (crizotinib) in ROS1-rearranged non-small cell lung cancer
2025-10-19 11:44:20
Check Details
Can all cancers with NTRK gene fusions be treated with larotrectinib?
2025-10-19 11:44:20
Check Details
How much does a box of larotrectinib cost? Do you have medical insurance?
2025-10-19 11:44:20
Check Details
Efficacy and Safety of Crizotinib (Xalkori) in Patients with Lung Cancer
2025-10-19 11:44:20
Check Details
Will larotrectinib be included in the national medical insurance in China in 2021?
2025-10-19 11:44:20
Check Details
Where can I buy larotrectinib in China? How much does a box cost?
2025-10-19 11:44:20
Check Details
Can the broad-spectrum anticancer drug larotrectinib be reimbursed by medical insurance?
2025-10-19 11:44:20
Check Details
Can cabozantinib (XL184) improve quality of life in metastatic RCC?
2025-10-19 11:44:20
Check Details
1
2
...
3908
3909
3910
3911
3912
3913
3914
...
4152
4153
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
The Cornerstone Therapy for Adrenocortical Carcinoma and Global Guidelines Update
2
Trodelvy® (Sacituzumab Govitecan-hziy): A Life-Changing ADC for Advanced Cancers
3
A Revolutionary Targeted Therapy for Hematological Malignancies
4
A New Option for Advanced Renal Cell Carcinoma Treatment
5
Trametinib (Mekinist): Precision MEK1/2 Inhibition Transforming Cancer Care Short Description:
6
Pirtobrutinib: A Novel BTK Inhibitor Offering Hope for Hematologic Cancer Patients Short Description:
7
Sacituzumab Govitecan: Trop-2 Targeted ADC Clinical Medication Guide
8
Fulvestrant (Faslodex) Breast Cancer Guide: Indications, Dosage and Safety Specifications
9
Adagrasib (Krazati): Full Guide to KRAS G12C Inhibitor for Cancer Treatment
10
Comprehensive Analysis of the Third-Generation EGFR-TKI
11
ATOMIC Study: Atezolizumab Plus Chemo Improves DFS in dMMR Stage III Colon Cancer
12
Oncology Immunotherapy vs Anti-Inflammatory Biologic: Dostarlimab vs Secukinumab - A Mechanism-Centered Comparison